Invitae, BioMarin Pharmaceutical Australia Pty Ltd., Praxis Precision Medicines, and Xenon Pharmaceuticals Inc. have partnered to offer Invitae’s comprehensive Epilepsy Panel to any child 24-95 months of age who has had an unprovoked seizure.
Genetic testing may bring you closer to understanding what’s causing your patient’s epilepsy, helping your patients and their caregivers benefit from deeper knowledge and timely care.
Sponsored by Biogen, this program provides no-cost genetic testing for Friedreich ataxia(FA), a neurodegenerative disease characterized by progressive ataxia (ataxic gait and limbs), dysarthria, dysphagia, decreased proprioception, distal muscle weakness, peripheral sensory neuropathy, absent lower limb tendon reflexes, spasticity, scoliosis, pes cavus, and hypertrophic cardiomyopathy. No-cost FA testing is available for patients 16 years of age or older, suspected of or have a clinical diagnosis of FA, and be a resident of the United States or Puerto Rico. The test must be ordered by a qualified healthcare provider.
In partnership with Passage Bio, this program provides physicians access to no-cost genetic testing for patients, who are suspected of having frontotemporal dementia (FTD), a clinically heterogeneous syndrome due to the progressive degeneration and atrophy of various regions of the frontal and temporal lobes of the brain.
Qualified healthcare providers can order no-cost genetic testing for patients, who meet eligibility criteria, to help determine if they have FTD.
The Alnylam Act® program was created to provide access to genetic testing and counseling to patients as a way to help people make more informed decisions about their health.
– While Alnylam provides financial support for this program, tests and services are performed by independent third parties
– Healthcare professionals must confirm that patients meet certain criteria to use the program
– Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient identifiable information. Alnylam may use healthcare professional contact information for research purposes
– Both genetic testing and genetic counseling are available in the U.S. and Canada
– Healthcare professionals or patients who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Alnylam product
– No patients, healthcare professionals, or payers, including government payers, are billed for this program
